Cargando…

Infliximab-Related Infusion Reactions: Systematic Review

OBJECTIVE: Administration of infliximab is associated with a well-recognised risk of infusion reactions. Lack of a mechanism-based rationale for their prevention, and absence of adequate and well-controlled studies, has led to the use of diverse empirical administration protocols. The aim of this st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lichtenstein, Lev, Ron, Yulia, Kivity, Shmuel, Ben-Horin, Shomron, Israeli, Eran, Fraser, Gerald M., Dotan, Iris, Chowers, Yehuda, Confino-Cohen, Ronit, Weiss, Batia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558633/ https://www.ncbi.nlm.nih.gov/pubmed/26092578 http://dx.doi.org/10.1093/ecco-jcc/jjv096

Ejemplares similares

Ashkenazi Jewish Origin Protects Against Formation of Antibodies to Infliximab and Therapy Failure
por: Ungar, Bella, et al.
Publicado: (2015)

Development and validation of novel algorithms to identify patients with inflammatory bowel diseases in Israel: an epi-IIRN group study
por: Friedman, Mira Y, et al.
Publicado: (2018)

Magnetic resonance enterography or video capsule endoscopy – what do Crohn’s disease patients prefer?
por: Lahat, Adi, et al.
Publicado: (2016)

Self‐reported treatment effectiveness for Crohn's disease using a novel crowdsourcing web‐based platform
por: Engel, Tal, et al.
Publicado: (2023)

Beyond borders: Do geographic correlations suggest shared environmental factors in inflammatory bowel diseases, Hodgkin lymphoma, and multiple sclerosis
por: Fay, Shmuel, et al.
Publicado: (2023)

Familial ulcerative colitis in Israeli Jews: its prevalence and clinical severity compared to sporadic disease
por: Ben-Horin, Shomron, et al.
Publicado: (2011)

Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays
por: Afonso, Joana, et al.
Publicado: (2016)

COVID-19 in Patients with Inflammatory Bowel Disease: The Israeli Experience
por: Lichtenstein, Lev, et al.
Publicado: (2022)

Delaying an infliximab infusion by more than 3 days is associated with a significant reduction in trough levels but not with clinical worsening
por: Ben-Shatach, Zohar, et al.
Publicado: (2022)

Acute Chest Pain as an Infusion Reaction to Vedolizumab
por: Levartovsky, Asaf, et al.
Publicado: (2022)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
por: Kashlan, Reem, et al.
Publicado: (2020)

Immune function in newborns with in-utero exposure to anti-TNFα therapy
por: Weiss, Batia, et al.
Publicado: (2022)

Association of Infliximab and Vedolizumab Trough Levels with Reported Rates of Adverse Events: A Cross-Sectional Study
por: Veisman, Ido, et al.
Publicado: (2021)

Helicobacter pylori prevalence and clinical significance in patients with quiescent Crohn’s disease
por: Lahat, Adi, et al.
Publicado: (2017)

Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical Trial
por: D’Haens, Geert, et al.
Publicado: (2023)

Immediate-type infliximab infusion reaction presenting as purpura
por: Soong, Laura, et al.
Publicado: (2018)

Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease
por: Grišić, Ana‐Marija, et al.
Publicado: (2021)

Predictors of infusion reactions during infliximab treatment in patients with arthritis
por: Kapetanovic, Meliha C, et al.
Publicado: (2006)

Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis
por: Mir, Fazia A., et al.
Publicado: (2018)

Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting
por: Checkley, L. Allyson, et al.
Publicado: (2018)

Effect of Standardized Infliximab Dose Rounding on an Outpatient Infusion Center
por: Park, Jiyeon Joy, et al.
Publicado: (2018)

Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
por: Schreiber, Stefan, et al.
Publicado: (2022)

Childhood Asthma – The Effect of Asthma Specialist Intervention on Asthma Control: A Retrospective Review
por: Rosman, Yossi, et al.
Publicado: (2021)

Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era
por: Schreiber, Stefan, et al.
Publicado: (2022)

Rapid infusion of infliximab biosimilars and the incidence and severity of infusion‐related reactions in patients with inflammatory bowel disease
por: Rusch, Caroline, et al.
Publicado: (2022)

Linear IgA dermatosis after infliximab infusion for ulcerative colitis
por: Bryant, Kelli D., et al.
Publicado: (2016)

Implementation and Evaluation of a Standard Operating Procedure for Pediatric Infliximab Infusions
por: Kelly, Maureen M., et al.
Publicado: (2019)

Efficacy of biological drugs in short-duration versus long-duration inflammatory bowel disease: a protocol for a systematic review and an individual-patient level meta-analysis of randomised controlled trials
por: Ben-Horin, Shomron, et al.
Publicado: (2019)

Successful Treatment of Tolosa-Hunt Syndrome after a Single Infusion of Infliximab
por: Halabi, Tarek, et al.
Publicado: (2018)

Taking Crohn’s Disease Personally
por: Chowers, Yehuda
Publicado: (2013)

One Size Does Not Fit All: The Case for Translational Medicine
por: Chowers, Yehuda
Publicado: (2019)

Volume of fluid consumption during preparation for colonoscopy is possibly the single most important determinant of bowel preparation adequacy
por: Gorelik, Yuri, et al.
Publicado: (2021)

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
por: Fitzgerald, Timothy, et al.
Publicado: (2021)

Decreasing Door-to-Door Times for Infliximab Infusions in a Children's Hospital Observation Unit
por: Sandberg, Kelly C., et al.
Publicado: (2019)

A quality improvement project reduces time spent at an inflammatory bowel disease infusion center with accelerated infliximab infusion protocol
por: Ong, Wan Chee, et al.
Publicado: (2022)

Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn’s disease: systematic review and meta-analysis
por: Tham, Yuen Sau, et al.
Publicado: (2018)

Therapeutic drug monitoring in inflammatory bowel disease
por: Kopylov, Uri, et al.
Publicado: (2014)

Optimizing biologic treatment in IBD: objective measures, but when, how and how often?
por: Ben-Horin, Shomron, et al.
Publicado: (2015)

Curcumin-QingDai Combination as Treatment for Moderate-Severe Ulcerative Colitis
por: Ben-Horin, Shomron, et al.
Publicado: (2022)

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator
por: Hinshaw, Amie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q7g808g1mub2ec5qlaa59mk50h